Oppenheimer reiterates an Outperform rating on Fulcrum Therapeutics with a $16 price target after the company announced that losmapimod’s REACH study had enrolled, putting the trial on track for a potential top-line readout in Q4 of 2024. The firm continues to believe losmapimod “could provide major under-the-radar upside” for Fulcrum shares. Given the unmet need in facioscapulohumeral muscular dystrophy, the bar to demonstrate benefit might be quite low, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics completes enrollment in Phase 3 trial of losmapimod in FSHD
- Fulcrum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
- Fulcrum Therapeutics (NASDAQ:FULC) Skyrockets After FDA Lifts Clinical Hold on Sickle Cell Disease Candidate
- Fulcrum shares should be up 30%-50% on hold lift, says Oppenheimer
- Fulcrum upgraded to Buy at Stifel after FDA lifts clinical hold on FTX-6058